Hannah Clarke

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.

Take a look through some of the notable data presentations at this year's ESMO Congress.

The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.

The agency issued a PDUFA target action date of June 14, 2027.

Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.

These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.

This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.

The completion of the first procedure marks the beginning of a controlled US commercial release.

Butterfly Medical has also submitted a premarket approval application to the FDA.

Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.

These FAQs outline key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from September 2026.

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.

The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for prebiopsy prostate cancer detection.

In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.

In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.

The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.

A limited market release of SpaceOAR Flex is expected to begin in the US later this year.

The PDUFA target action date is in the fourth quarter of 2026.

The approval is supported by data from the phase 3 LITESPARK-011 trial.

Positive safety and efficacy data from 4 clinical studies supported the CE marking.

The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.